Summary: Date: 4/23/2008 Length: 00:12:14 Size: 5.60MB Thought Leaders: John Lagus, VP of Business and Corporate Development, IDIS This final installment in a three-part series covers how named patient programs can be used for market development, assist with regulatory challenges, address reimbursement issues, and develop key opinion leaders, and more. Play Podcast Free Whitepaper Download: "Enhancing Global Market Access Strategies with Named Patient Programs" Download RelatedWhite Paper For more information on how you can be featured in a podcast, contact Dan Limbach at dlimbach@pharmavoice.com or call him at (847) 594-0157.
